The maker of Vagisil feminine hygiene products has successfully overturned a ruling that denied its bid to stop a European competitor from registering Vagisan as a trade mark in Australia.
The TGA has ordered former senator and vet David Leyonhjelm to take down misleading tweets spruiking a medication used to treat parasite infestations in horses as “probably the most economical source” to treat COVID-19.
The Federal Court has delayed a 15-day hearing in a pneumococcal vaccine patent dispute between Merck Sharp & Dohme and Pfizer after the sudden death of a family member of one of Pfizer’s expert witnesses.
A group of women harmed by pelvic mesh devices produced by Johnson & Johnson have accused it of persisting with a “wreckage” of a case in which one of its own doctors admitted the pharmaceutical company knew of the risks posed by the implants at they time they were sold worldwide.
An upcoming class action trial over alleged side effects resulting from the Hendra virus horse vaccine, which will commence shortly after a COVID-19 vaccine is rolled out in Australia, will raise “timely” issues concerning vaccine safety, a judge has heard.
The judge who found J&J’s pelvic mesh implants defective in a high stakes class action ruling mde a “pervasive error” in disregarding the knowledge and views of the applicants’ doctors, an appeals court has heard.
Multinational pharmaceutical company Dr Reddy’s has launched a lawsuit against a Melbourne biotechnology company’s directors as well as venture capital firm OneVentures, alleging they sold it dodgy lice treatment which was forecasted to make over US$100 million.
Drug giant Merck Sharp & Dohme has brought a cross appeal in its long-running intellectual property dispute with Pfizer’s Wyeth over the top selling Prevnar 13 pneumococcal vaccine.
Botox maker Allergan has appealed a court judgment tossing most of trade mark case against an Australian cosmetics company that sells topical creams as Botox alternatives.
Pfizer unit Wyeth is seeking to overturn part of a judge’s decision in its high-stakes patent dispute with Merck Sharp & Dohme that found claims in two of its patents relating to the blockbuster Prevnar 13 pneumococcal vaccine were invalid.